CN104039330A - 化疗耐药性的癌症的联合治疗 - Google Patents

化疗耐药性的癌症的联合治疗 Download PDF

Info

Publication number
CN104039330A
CN104039330A CN201280058094.7A CN201280058094A CN104039330A CN 104039330 A CN104039330 A CN 104039330A CN 201280058094 A CN201280058094 A CN 201280058094A CN 104039330 A CN104039330 A CN 104039330A
Authority
CN
China
Prior art keywords
day
romidepsin
decitabine
azacitidine
cytidine analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280058094.7A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·A·科普兰三世
汉·温·图恩
西蒙·詹姆士·库珀
劳拉·安·马洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN104039330A publication Critical patent/CN104039330A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
CN201280058094.7A 2011-09-26 2012-09-26 化疗耐药性的癌症的联合治疗 Pending CN104039330A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539452P 2011-09-26 2011-09-26
US61/539,452 2011-09-26
PCT/US2012/057175 WO2013049093A1 (en) 2011-09-26 2012-09-26 Combination therapy for chemoresistant cancers

Publications (1)

Publication Number Publication Date
CN104039330A true CN104039330A (zh) 2014-09-10

Family

ID=47018520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280058094.7A Pending CN104039330A (zh) 2011-09-26 2012-09-26 化疗耐药性的癌症的联合治疗

Country Status (12)

Country Link
US (1) US20130244950A1 (enExample)
EP (1) EP2760456A1 (enExample)
JP (1) JP2014526564A (enExample)
KR (1) KR20140069271A (enExample)
CN (1) CN104039330A (enExample)
AU (1) AU2012316266B2 (enExample)
CA (1) CA2849903A1 (enExample)
HK (1) HK1200354A1 (enExample)
IL (1) IL231662A0 (enExample)
MX (1) MX2014003591A (enExample)
WO (1) WO2013049093A1 (enExample)
ZA (1) ZA201402195B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106310268A (zh) * 2015-06-18 2017-01-11 复旦大学 一种治疗三阴性乳腺癌的药物组合物
CN114931626A (zh) * 2022-05-09 2022-08-23 中国人民解放军军事科学院军事医学研究院 罗米地辛在防治高原红细胞增多血症中的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164392A1 (en) 2015-04-06 2016-10-13 The Johns Hopkins University A h3t3a mutant protein efficiently reduces h3t3p and causes increased cell death of rapidly dividing cells
WO2017034234A1 (ko) * 2015-08-21 2017-03-02 서울대학교 산학협력단 Hdac 억제제 내성을 갖는 암 치료용 복합제제
US20250263797A1 (en) * 2020-12-22 2025-08-21 Vilnius University Clear cell renal cell carcinoma biomarkers and uses therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
CN1997361A (zh) * 2004-02-25 2007-07-11 安斯泰来制药有限公司 抗肿瘤药物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH064872A (ja) 1992-06-19 1994-01-14 Sony Corp 光ディスク再生装置
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
EP1313872A1 (en) 2000-09-01 2003-05-28 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
WO2010008731A1 (en) * 2008-06-16 2010-01-21 Tigris Pharmaceuticals, Inc. Methods for determining sensitivity to aminoflavones
CA2789365A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
CN1997361A (zh) * 2004-02-25 2007-07-11 安斯泰来制药有限公司 抗肿瘤药物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
张保宁等: "三阴性乳腺癌研究进展:第31届圣・安东尼奥乳腺癌研讨会报道", 《中华乳腺病杂志（电子版）》 *
张保宁等: "三阴性乳腺癌研究进展:第31届圣・安东尼奥乳腺癌研讨会报道", 《中华乳腺病杂志（电子版）》, vol. 3, no. 1, 28 February 2009 (2009-02-28), pages 5 - 8 *
彭恩兰等: "DNA甲基化转移酶抑制剂和组蛋白脱乙酰化酶抑制剂的体外抗肿瘤作用", 《现代肿瘤医学》 *
李莲等: "5-氮-2’-脱氧胞苷抗肿瘤作用的研究进展", 《临床肿瘤学杂志》 *
范江等: "5-aza-2’deoxycytidine联合trichostatin A抑制乳腺癌细胞增殖能力的研究", 《中国癌症杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106310268A (zh) * 2015-06-18 2017-01-11 复旦大学 一种治疗三阴性乳腺癌的药物组合物
CN106310268B (zh) * 2015-06-18 2018-12-21 复旦大学 一种治疗三阴性乳腺癌的药物组合物
CN114931626A (zh) * 2022-05-09 2022-08-23 中国人民解放军军事科学院军事医学研究院 罗米地辛在防治高原红细胞增多血症中的用途

Also Published As

Publication number Publication date
AU2012316266A1 (en) 2013-05-02
CA2849903A1 (en) 2013-04-04
MX2014003591A (es) 2014-09-08
HK1200354A1 (en) 2015-08-07
ZA201402195B (en) 2015-06-24
AU2012316266B2 (en) 2015-07-30
JP2014526564A (ja) 2014-10-06
IL231662A0 (en) 2014-05-28
KR20140069271A (ko) 2014-06-09
US20130244950A1 (en) 2013-09-19
EP2760456A1 (en) 2014-08-06
WO2013049093A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP6063628B2 (ja) ５−アザシチジンを用いる、非小細胞肺癌の治療方法
JP7047148B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
EP3986403A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US20120316203A1 (en) Compositions and Methods for Inhibition of Cancers
CN106456635A (zh) Mdm2抑制剂的间歇给药
CN108136207A (zh) 用于治疗癌症的联合疗法
CN104039330A (zh) 化疗耐药性的癌症的联合治疗
US20230053688A1 (en) Methods to alter latency in ebv+ malignancies
AU2013202507A1 (en) Inhibition of drug resistant cancer cells
US20120053211A1 (en) Treatment of pancreatic cancer
AU2012312308B2 (en) Romidepsin and 5-azacitidine for use in treating lymphoma
WO2013085902A1 (en) Combination therapy methods for treating an inflammatory breast cancer
JP7282072B2 (ja) 肺がんの治療に使用するための組み合わせ
RU2754131C1 (ru) Комбинированная терапия ингибитором ezh2
US20130116298A1 (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment
TW202329968A (zh) 包含mdm2抑制劑、bcl2抑制劑和低甲基化劑的藥物組合及其用於治療血液惡性腫瘤之用途
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害
NZ622752B2 (en) Romidepsin and 5 - azacitidine for use in treating lymphoma
HK1170667A (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140910